EA200700876A1 - AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 - Google Patents
AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2Info
- Publication number
- EA200700876A1 EA200700876A1 EA200700876A EA200700876A EA200700876A1 EA 200700876 A1 EA200700876 A1 EA 200700876A1 EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A EA200700876 A EA 200700876A EA 200700876 A1 EA200700876 A1 EA 200700876A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- angiopoetin
- specifically binding
- agents specifically
- antibodies
- fragments
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Раскрыты специфические связывающие агенты, такие как полностью человеческие антитела, которые связывают ангиопоэтин-2. Раскрыты также фрагменты тяжёлых цепей, фрагменты лёгких цепей и участки, определяющие комплементарность (CDR), в составе антител, а также способы получения и применения этих антител.Specific binding agents are disclosed, such as fully human antibodies that bind angiopoietin-2. Also disclosed are fragments of heavy chains, fragments of light chains, and regions that determine complementarity (CDR) in the composition of antibodies, as well as methods for producing and using these antibodies.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62016104P | 2004-10-19 | 2004-10-19 | |
US10/982,440 US7658924B2 (en) | 2001-10-11 | 2004-11-04 | Angiopoietin-2 specific binding agents |
PCT/US2005/037911 WO2006045049A1 (en) | 2004-10-19 | 2005-10-19 | Angiopoietin-2 specific binding agents |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200700876A1 true EA200700876A1 (en) | 2007-10-26 |
EA011866B1 EA011866B1 (en) | 2009-06-30 |
Family
ID=39608222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200700876A EA011866B1 (en) | 2004-10-19 | 2005-10-19 | Angiopoetin-2 specific binding agents |
Country Status (10)
Country | Link |
---|---|
JP (2) | JP2008520188A (en) |
CN (1) | CN101495513B (en) |
BR (1) | BRPI0518209A (en) |
EA (1) | EA011866B1 (en) |
IL (1) | IL182279A0 (en) |
MA (1) | MA29015B1 (en) |
MX (1) | MX2007004247A (en) |
RU (2) | RU2404992C2 (en) |
SG (1) | SG156668A1 (en) |
ZA (1) | ZA200704020B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014100834A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520188A (en) * | 2004-10-19 | 2008-06-19 | アムジエン・インコーポレーテツド | Angiopoietin-2 specific binding substance |
JO3182B1 (en) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | High Affinity Human Antibodies to Human Angiopoietin-2 |
EA022546B1 (en) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Method for inhibiting growth of ehrlich carcinoma in laboratory animal |
EP3210625B1 (en) * | 2011-09-30 | 2019-08-28 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica) |
NZ627859A (en) * | 2012-01-23 | 2015-09-25 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
AR100270A1 (en) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | ANTIBODIES ANG2 |
KR102512940B1 (en) | 2014-08-28 | 2023-03-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | High-purity quinoline derivative and method for manufacturing same |
JP6792546B2 (en) | 2015-02-25 | 2020-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | How to suppress bitterness of quinoline derivatives |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
CN106075448A (en) * | 2016-07-25 | 2016-11-09 | 广州道瑞医药科技有限公司 | ANGPT2 inhibitor is used for treating the application in angiomatous medicine in preparation |
CN106512006A (en) * | 2016-07-25 | 2017-03-22 | 广州道瑞医药科技有限公司 | Application of ANGPT2 secretion inhibitor to preparation of medicine for treating hemangiomas |
CN109096368B (en) * | 2018-09-30 | 2021-07-20 | 华南理工大学 | Polypeptide with antioxidant and liver protecting activities, gene for encoding polypeptide, preparation method and application thereof |
JP7177284B2 (en) * | 2019-02-25 | 2022-11-22 | ファームアブシン・インコーポレイテッド | Anti-ANG2 antibody and use thereof |
CN112126671B (en) * | 2020-08-18 | 2021-08-31 | 中山大学附属第五医院 | Application of streptococcus agalactiae streptococcus agalactiae in treating endometriosis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60003011T2 (en) * | 1999-03-26 | 2004-04-08 | Regeneron Pharmaceuticals, Inc. | MODULATING VASCER PERMABILITY BY TIE2 RECEPTOR ACTIVATORS |
US7205275B2 (en) * | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
WO2003030883A1 (en) * | 2001-10-12 | 2003-04-17 | Kosmos Pharma | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
JP2008520188A (en) * | 2004-10-19 | 2008-06-19 | アムジエン・インコーポレーテツド | Angiopoietin-2 specific binding substance |
-
2005
- 2005-10-19 JP JP2007538066A patent/JP2008520188A/en active Pending
- 2005-10-19 RU RU2007118670/13A patent/RU2404992C2/en not_active IP Right Cessation
- 2005-10-19 SG SG200907008-7A patent/SG156668A1/en unknown
- 2005-10-19 EA EA200700876A patent/EA011866B1/en not_active IP Right Cessation
- 2005-10-19 MX MX2007004247A patent/MX2007004247A/en active IP Right Grant
- 2005-10-19 CN CN200580043569.5A patent/CN101495513B/en not_active Expired - Fee Related
- 2005-10-19 BR BRPI0518209-3A patent/BRPI0518209A/en not_active IP Right Cessation
-
2007
- 2007-03-28 IL IL182279A patent/IL182279A0/en unknown
- 2007-05-11 MA MA29892A patent/MA29015B1/en unknown
- 2007-05-18 ZA ZA200704020A patent/ZA200704020B/en unknown
-
2010
- 2010-08-05 RU RU2010132956/10A patent/RU2010132956A/en not_active Application Discontinuation
-
2011
- 2011-03-30 JP JP2011075243A patent/JP2011207882A/en not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014100834A1 (en) * | 2012-12-21 | 2014-06-26 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
US9534007B2 (en) | 2012-12-21 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity |
Also Published As
Publication number | Publication date |
---|---|
IL182279A0 (en) | 2007-07-24 |
JP2008520188A (en) | 2008-06-19 |
SG156668A1 (en) | 2009-11-26 |
BRPI0518209A (en) | 2008-11-04 |
CN101495513B (en) | 2014-08-06 |
EA011866B1 (en) | 2009-06-30 |
JP2011207882A (en) | 2011-10-20 |
MX2007004247A (en) | 2007-06-12 |
MA29015B1 (en) | 2007-11-01 |
RU2010132956A (en) | 2012-02-10 |
ZA200704020B (en) | 2008-06-25 |
RU2404992C2 (en) | 2010-11-27 |
RU2007118670A (en) | 2008-12-27 |
CN101495513A (en) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200700876A1 (en) | AGENTS SPECIFICALLY BINDING ANGIOPOETIN-2 | |
RS28904A (en) | Angiopoietin-2 specific binding agents | |
EA200400526A1 (en) | AGENTS SPECIFICALLY CONNECTING WITH HUMAN ANGIOPOETIN-2 | |
EA201001335A1 (en) | ANTIBODIES DIRECTED AGAINST ANGIOPOETHINA-1 AND ANGIOPOETINA-2 AND THEIR APPLICATION | |
EA201070888A1 (en) | ANTIBODIES AND THEIR DERIVATIVES | |
NO2017032I1 (en) | bezlotoksumab | |
PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
EA200800812A1 (en) | Antibody Anti-CD3 Compositions | |
PH12016500658A1 (en) | Human anti-alpha-synuclein autoantibodies | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
EP1912674B8 (en) | Bispecific single chain fv antibody molecules and methods of use thereof | |
WO2005112564A3 (en) | Germline and sequence variants of humanized antibodies and methods of making and using them | |
TW200617025A (en) | Il-17 antagonistic antibodies | |
WO2003100033A3 (en) | ANTI-αvβ6 ANTIBODIES | |
WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
TW200635946A (en) | Binding proteins specific for human matriptase | |
EA200801172A1 (en) | LIGANDS HAVING A SPECIFICITY OF BINDING WITH RESPECT TO THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR (EGFR) AND / OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), AND THEIR APPLICATION | |
EA201491575A1 (en) | ANTIBODIES TO MATRIX METALLOPROTEINASE 9 | |
EP2192132A3 (en) | Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation | |
WO2008133641A3 (en) | Antibodies directed to gpnmb and uses thereof | |
WO2006058890A3 (en) | Method of producing antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |